Coming Soon! CE on Shared Decision Making for Stage IV Melanoma

Past offerings (available for review, not credit):

CME/CE on BRAF/MEK Inhibitor Therapy for Melanoma

Join our esteemed faculty—Krista M. Rubin, RN, MS, FNP-BC, and Ryan J. Sullivan, MD—as they explore optimal incorporation of targeted therapy in melanoma. This case addresses BRAF testing, appropriate use of BRAF/MEK inhibitor therapy, the profiles of the 3 targeted therapy options, side-effect management, and adherence/pharmacologic considerations.

CME/CE on interdisciplinary care for management of complex irAEs.

JCO Oncology Practice (JCO OP) CME/CE/CPE supplement using cases to illustrate optimal interdisciplinary management of immune-related adverse events, Immuno-Oncology Essentials: Applications in Clinical Scenarios.

Melanoma Therapeutics and Side-Effect Management: Making a Difference from the Outset 

Click here to visit, learn more, and view the complete accreditation information.

A new JADPRO CE supplement on the management of immune-related adverse events, Immuno-Oncology Therapy Essentials: Proactive Management of Immune-Related Adverse Events.

Supported by an independent educational grant from Merck & Co., Inc.

The newly launched site,, a dedicated portal of continuing education initiatives in cancer, features this first activity on managing side effects associated with newer melanoma therapies.  Showcasing 5 cases representing patients at varied stages of melanoma as well as the range of newer melanoma therapeutic options, this highly interactive activity will assist you in incorporating the Care Step Pathways and other tools from the MNI in real-world clinical scenarios. This is a free activity offering AMA PRA Category 1 Credits™, Continuing Nursing Education contact hours, as well as pharmacotherapy contact hours for advanced practice registered nurses.